Board summary
Key figures
51,557
Registered population
51.9% aged 18–64
32.2%
Aged 65+
ICB 24.3% · England 17.9%
1.8%
Ethnic minority (non-White)
0.5% Asian · England 9.6%
10.3%
In IMD quintile 1
ICB 10.9% · England 21.0%
~4,700
Core20 residents (est.)
Resident basis; registered basis ~5,016 · see page 3
10,589
Hypertension register
+7.47% in 3 yrs · England +5.60%
340
SMI register
19.7% of Herefordshire, County of (LAD)'s
1,389
COPD register
Reviews -6.53% in 3 yrs
Forecast to 2030
12,633
Hypertension patients, 2030
+2,044 on today
98.1%
QRISK ≥20% on statins, 2030
+13.13pp over 3 yrs
7.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control trails England and fell over time.
Hypertension treatment to target is 66.8% (England 70.3%; ICB 70.4%) and fell 3.2% (England +3.6%), despite 89.9% having a recent reading.
Preventive lipid prescribing and breast screening outpace England.
QRISK ≥ 20% lipid-lowering therapy rose +28.2% to 59.6% (England +6.2% to 63.6%), and breast screening coverage reaches 76.7% (England 69.9%).
Population, age and ethnicity
Adults aged 65+ represent 32.2% of registered patients, well above England's 17.9%
North & West Herefordshire PCN has 51,557 registered patients. Adults aged 65+ make up 32.2% (16,587 patients), exceeding the LAD (28.3%), the ICB (24.3%) and England (17.9%). Working-age adults (18–64) represent 51.9% and children (0–17) 15.9%. Census data shows 98.2% of local residents identify as White (LAD 96.9%, ICB 94.6%, England 81.1%), with an ethnic minority share of 1.8%. Registered population is projected to grow 2.4% by 2030 under an unverified ONS methodology. Age figures describe registered patients, whereas ethnicity describes Census usual residents in associated areas.
Age profile
65+: ICB 24.3%, England 17.9%
Ethnicity
Older people · falls rows are Herefordshire, County of (LAD) local-authority (LA) data, not PCN
| Measure | Local | West Midlands | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Herefordshire LA) | 1,472 | 1,847 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.1% | — | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.2% | — | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Herefordshire LA) | 772 | 922 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Herefordshire LA) | 10.4 | 17.5 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 10.3% overall and concentrated entirely within Ryeland Surgery
The PCN Core20 cohort is 10.3%, above the LAD (7.8%) but below the ICB (10.9%) and England (21.0%). Average IMD decile is 4.7 (LAD 5.5; ICB 6.1; England 5.5). On reconciliation, weighted practice share is 9.7%, a 0.61 percentage points difference from the PCN rate. Within practices, Core20 share is concentrated at Ryeland Surgery (25.9%; estimated 5,016 patients), whereas the remaining four practices record 0.0%. Resident deciles 1 and 2 comprise about 4,700 people (2,756 aged 18-64, 1,000 aged 0-17, and 944 aged 65+).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
340
SMI register
0.66% recorded prevalence
251
Learning disability register
0.48% recorded prevalence
21
Care homes, 597 beds
In the PCN catchment
8.7%
Provide unpaid care
Herefordshire, County of (LAD), Census 2021
The PCN records 251 patients with learning disabilities (0.5% prevalence vs 0.6% LAD, ICB, and England) and 340 with severe mental illness (0.7% vs England 1.0%). The catchment includes 21 care homes with 597 beds. Countywide, an autumn 2025 snapshot recorded 16 people sleeping rough.
Severe mental illness: physical health checks
SMI prevalence is 0.7% (England 1.0%). Over 2023 to 2025, recorded BMI fell 3.5 pp to 79.6% (England +5.1 pp) and alcohol recording fell 0.6 pp to 79.6% (England +5.4 pp). Blood pressure checks reached 82.8% (England 83.4%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,589
Hypertension register
+7.47%
Register growth, 3 yrs
Herefordshire, County of (LAD) +10.36% · England +5.60%
+0.49pp
BP control, under 80
≤140/90 · −0.60pp aged 80+
+2,044
More patients by 2030
Forecast 12,633 (23.61%)
Hypertension case-finding and control
Hypertension register prevalence is 20.4% (10,589 patients), exceeding England (15.2%), the LAD (19.2%) and the ICB (18.7%). While 89.9% of patients have a recent blood pressure reading (England 90.0%), treatment to threshold is 66.8%, trailing England (70.3%), the ICB (70.4%) and the LAD (68.6%). Furthermore, control fell 3.2% over 2023 to 2025 (England +3.6%). For patients aged 80 and over, control is 78.6% (England 81.2%) and fell 0.8% (England +2.2%), while for under-80s it is 66.0% (England 67.8%). Lower control rates than England across both age cohorts suggest a focus on clinical titration and structured recalls for uncontrolled patients.
Lipids and statins
Lipid-lowering therapy for patients with QRISK ≥ 20% rose 28.2% over 2023 to 2025 (England +6.2%) to 59.6%, remaining below England (63.6%) and the ICB (61.4%). Coverage among patients with CKD is 65.6% (England 70.3%). Lower uptake across high-risk groups suggests reviewing primary prevention prescribing pathways.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 130,099 | £2.10 | £2.17 | £1.86 | £273,208 |
| Cardiovascular (all), 2025 | 170,595 | £4.01 | £4.41 | £3.33 | £684,086 |
In 2026, the PCN prescribed 130,099 lipid-regulating drug items at £2.10 per item (England £1.86; ICB £2.17; LAD £2.44), spending £273,208. The PCN spends £31,224 more than at England's unit cost, but £9,107 less than at ICB unit cost across 130,099 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.53%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.17%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.7% (1,389 patients; England 1.9%; ICB 2.2%). Over 2023 to 2025, COPD reviews fell 6.5% to 72.2% (England +2.8% to 76.4%; ICB +0.5% to 76.8%). Asthma prevalence is 7.2% (3,556 patients; England 6.6%), with annual reviews at 65.9% (England 65.7%), leaving an estimated 1,213 unreviewed patients. Asthma prescribing for ages 5-19 reaches 1,884 items per 1,000 (England 1,488). Local audit can test whether higher youth prescribing reflects reactive management.
Cancer register and children's immunisation
Cancer register prevalence is 6.3% (3,255 patients; England 3.8%; ICB 5.1%). In Q1 2025/26, 6-in-1 coverage at 12 months reached 96.0% (England 91.0%). At age 5, MMR first-dose coverage was 94.4% (England 91.7%) and second-dose was 87.9% (England 82.8%), a difference of 6.5 pp, while 4-in-1 booster coverage reached 88.8% (England 80.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
56.2%
Herefordshire and Worcestershire ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~770
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Herefordshire and Worcestershire ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 52.4% | 53.2% | 23% | 706 |
| Bowel | 51.4% | 47.0% | 15% | 657 |
| Breast | 88.9% | 85.4% | 28% | 611 |
| Lung | 32.1% | 33.8% | 13% | 473 |
| Skin cancer | 86.3% | 87.8% | 13% | 314 |
In 2022, 56.2% of cancers across NHS Herefordshire and Worcestershire ICB were diagnosed at stage 1 or 2 (2,285 of 4,068 with a known stage), exceeding England (55.3%) but 18.8 pp below the 75.0% national ambition. Reaching 75.0% required 766 extra early diagnoses, while the ICB early share fell 2.7 pp from 2013 to 2022. Stage was known for 68.0% of cases (4,068 of 5,984). ICB staging cannot evaluate PCN care. PCN cancer prevalence is 6.3% (3,255 patients; England 3.8%), and cervical screening (ages 25-49) is 70.3% (England 66.8%), though Kington Medical Practice trails at 64.2%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Wye Valley NHS Trust met the 62-day cancer referral to treatment standard at 85.1%, ahead of The Shrewsbury and Telford Hospital NHS Trust (75.1%), England (71.2%), NHS Herefordshire and Worcestershire Integrated Care Board (61.7%) and Worcestershire Acute Hospitals NHS Trust (53.0%). For the 28-day faster diagnosis standard, Wye Valley NHS Trust achieved 86.5%, alongside The Shrewsbury and Telford Hospital NHS Trust (86.6%), the ICB (83.0%) and England (79.3%). For diagnostics, Wye Valley NHS Trust reported 0.2% waiting 6+ weeks for computed tomography and 18.2% for MRI (England 9.9% and 21.4%).
| Pathways within standard (%) | Wye Valley | Worcestershire Acute | Shrewsbury and Telford | Herefordshire and Worcestershire ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 86.52 | 82.50 | 86.60 | 83.05 | 79.32 |
| 31-day treatment (96%) | 96.25 | 86.98 | 98.10 | 89.95 | 92.50 |
| 62-day referral to treatment (85%) | 85.14 | 52.99 | 75.10 | 61.71 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wye Valley | Worcestershire Acute | Shrewsbury and Telford | England |
|---|---|---|---|---|
| MRI | 18.23 | 22.51 | 16.87 | 21.40 |
| CT | 0.16 | 11.09 | 0.83 | 9.92 |
| Echocardiography | 30.24 | 10.25 | 22.69 | 28.48 |
| Colonoscopy | 40.00 | 9.91 | 7.80 | 30.83 |
| Gastroscopy | 26.09 | 9.53 | 6.14 | 29.02 |
| All 15 DM01 tests | 19.35 | 30.61 | 20.58 | 23.14 |
| Community services activity | Worcestershire residents | Herefordshire and Worcestershire ICB |
|---|---|---|
| Care contacts | 82,605 | 124,085 |
| Referrals | 17,645 | 23,130 |
| Patients with a contact | 21,545 | 30,665 |
Community services (residents of Worcestershire), Jun 2026 (provisional). In Jun 2026, provisional community services data record that 67.4% of contacts with Herefordshire residents were for adults aged 65 and over (29,080 of 43,135 contacts). This activity is measured at local authority level rather than PCN level, reflecting substantial elder care utilisation across the surrounding health economy.
Practice variation and patient experience
Phone ease spans 42.9 pp and QOF vaccination spans 58.5 pp across practices
In 2025/26, QOF overall achievement was 87.0% at Kington Medical Practice, while Tenbury Surgery and Weobley & Staunton On Wye Surgeries each achieved 98.3%, compared with 92.5% in England. In the vaccination and immunisation domain, Ryeland Surgery achieved 40.6% against England's 55.2%, whereas Tenbury Surgery achieved 99.1%, spanning a range of 58.5 pp from Ryeland Surgery to Tenbury Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Weobley & | 133 | 0.0 | 98.3% | 77.3% | 92.8% |
| Tenbury Surgery | 118 | 0.0 | 82.1% | 81.5% | 91.6% |
| Mortimer Medical | 119 | 0.0 | 63.4% | 80.6% | 79.9% |
| Ryeland Surgery | 125 | 25.9 | 70.1% | 84.1% | 76.9% |
| Kington Medical | 113 | 0.0 | 55.4% | 78.9% | 72.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 compared measures trail England's three-year change across reviews and registers
Fourteen of 25 compared measures trail England's three-year change. Annual heart failure reviews fell 6.4% over 2023 to 2025 to 73.9%, whereas England rose 8.7% to 78.5%. Recorded BMI checks for patients on the mental health register fell 3.5 pp to 79.6% (England +5.1 pp to 82.1%), while learning disability register prevalence fell 0.8% (England +5.4%). Conversely, lipid-lowering therapy for QRISK ≥ 20% rose 28.2% over 2023 to 2025 against +6.2% in England.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
BMI record (SMI)
Hypertension treated to target
Learning disability register
QRISK statin treatment
Diabetes statin (CVD)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Herefordshire, County of (LAD) | Asset | PCN | Herefordshire, County of (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (597 beds) | n/a | Schools (catchment) | 88 | n/a |
| Children's centres | 1 | 7 | Places of worship | 206 | 341 |
| Libraries | 3 | 9 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 21 | 43 |
| Primary academies | 13 | 28 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension recall and titration review
Among 10,589 hypertension patients (20.4% vs England 15.2%), 89.9% have a recent BP reading, but control is 66.8% (LAD 68.6%, ICB 70.4%, England 70.3%) and fell 3.2% over 2023 to 2025 (England +3.6%). For discussion: run pharmacist- or nurse-led recall and titration clinics for patients above age-specific BP thresholds. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Respiratory review and prescribing audit
Asthma reviews cover 65.9% of 3,556 patients (7.2% prevalence; England 65.7%), leaving 1,213 unreviewed, with 5-19 prescribing at 1,884 per 1,000 (England 1,488). COPD reviews fell 6.5% to 72.2% across 1,389 patients (England +2.8%). For discussion: standardise respiratory review templates and recall unreviewed patients and children with frequent prescribing. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Inclusion health checks and validation
Learning disability prevalence is 0.5% (251 patients vs 0.6% LAD, ICB, England; gap +52 to +77) and fell 0.8% over 2023 to 2025 (England +5.4%). SMI BMI checks (340 patients) fell 3.5 pp to 79.6% (England +5.1 pp). Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care alignment (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted deprivation outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall alignment (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Telephone and triage access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension recall and titration review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Respiratory review and prescribing audit (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Inclusion health checks and validation (p12) | Learning disability register · Learning disability: QOF prevalence · Severe mental illness register | 75% annual health checks (Network Contract DES) · Oliver McGowan · MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
